Biopsies: Next-generation biospecimens for tailoring therapy

Nature Reviews Clinical Oncology

Volumn 10, Issue 8, 2013, Pages 437-450

  Basik, Mark ^a   Aguilar Mahecha, Adriana ^a   Rousseau, Caroline ^a   Diaz, Zuanel ^a   Tejpar, Sabine ^b   Spatz, Alan ^a   Greenwood, Celia M T ^a   Batist, Gerald ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; B RAF KINASE INHIBITOR; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PRESERVATION SOLUTION; PROGESTERONE RECEPTOR; REAGENT; RNA;

BONE METASTASIS; BRAIN METASTASIS; BREAST TUMOR; CANCER RESISTANCE; CIRCULATING TUMOR CELL; CRYOPRESERVATION; DRUG SENSITIVITY; EGFR GENE; ENZYME REACTIVATION; FINE NEEDLE ASPIRATION BIOPSY; GENE MUTATION; HEALTH CARE FACILITY; HEMOPERITONEUM; HISTOPATHOLOGY; HUMAN; INFORMATION PROCESSING; LIVER BIOPSY; LIVER HEMORRHAGE; LIVER METASTASIS; LUNG BIOPSY; MEDICAL DECISION MAKING; MEDICAL ETHICS; MELANOMA; METASTATIC MELANOMA; ONCOGENE K RAS; PAIN; PNEUMOTHORAX; PRIORITY JOURNAL; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; REVIEW; TISSUE PRESERVATION; TRANSTHORACIC BIOPSY; TUMOR BIOPSY;

EID: 84881477907     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.101     Document Type: Review

References (139)

1. Lovly, C. M. et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE 7, e35309 (2012
2. Von Hoff, D. D. et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28, 4877-4883 (2010
3. Roychowdhury, S. et al. Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci. Transl. Med. 3, 111ra121 (2011
4. Desai, A. N. & Jere, A. Next-generation sequencing: Ready for the clinics? Clin. Genet. 81, 503-510 (2012
5. Blow, N. Biobanking: Freezer burn. Nat. Methods 6, 173-178 (2009
6. International Cancer Genome Consortium et al. International network of cancer genome projects. Nature 464, 993-998 (2010
7. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008
8. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011
9. Cancer Genome Atlas Research Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012
10. Cancer Genome Atlas Research Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012
11. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012
12. The Cancer Genome Atlas. TCGA Tissue Sample Requirements: High Quality Requirements Yield High Quality Data [online ], http://cancergenome.nih.gov/ cancersselected/biospeccriteria (2013
13. Koh, S. S. et al. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Mod. Pathol. 25, 828-837 (2012
14. Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809-813 (2009
15. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010
16. Turajlic, S. et al. Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res. 22, 196-207 (2012
17. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
18. Aurilio, G. et al. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol. http://dx.doi.org/10.3109/0284186X.2012.754990.
19. Botteri, E. et al. Biopsy of liver metastasis for women with breast cancer: Impact on survival. Breast 21, 284-288 (2012
20. Gray, J. Cancer: Genomics of metastasis. Nature 464, 989-990 (2010
21. Shi, H. et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B RAF inhibitor resistance. Nat. Commun. 3, 724 (2012
22. Doebele, R. C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472-1482 (2012
23. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012
24. Gorges, T. M. & Pantel, K. Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol. Immunother. 62, 931-939 (2013
25. US National Library of Medicine. Clinicaltrials.gov [online], http://clinicaltrials.gov/show/NCT00382018 (2013
26. Dawson, S. J. et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N. Engl. J. Med. 368, 1199-1209 (2013
27. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012
28. Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108-112 (2013
29. Overman, M. J. et al. Use of research biopsies in clinical trials: Are risks and benefits adequately discussed? J. Clin. Oncol. 31, 17-22 (2013
30. Goulart, B. H. et al. Trends in the use and role of biomarkers in phase I oncology trials. Clin. Cancer Res. 13, 6719-6726 (2007
31. Subramanian, J& Simon, R. Gene expression-based prognostic signatures in lung cancer: Ready for clinical use? J. Natl Cancer Inst. 102, 464-474 (2010
32. Liu, G. et al. Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer. J. Thorac. Oncol. 7, 316-322 (2012
33. Choi, Y. L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734-1739 (2010
34. Sharma, M. R. & Schilsky, R. L. Role of randomized phase III trials in an era of effective targeted therapies. Nat. Rev. Clin. Oncol. 9, 208-214 (2011
35. Amir, E. et al. Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat. Rev. 38, 708-714 (2011
36. Amir, E. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 30, 587-592 (2012
37. Chia, S. Testing for discordance at metastatic relapse: Does it matter? J. Clin. Oncol. 30, 575-576 (2012
38. Niikura, N. et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J. Clin. Oncol. 30, 593-599 (2012
39. Watanabe, T. et al. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis. Colon Rectum 54, 1170-1178 (2011
40. Artale, S. et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin. Oncol. 26, 4217-4219 (2008
41. Kim, E. et al. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov. 1, 44-53 (2011
42. Tran, B. et al. Feasibility of real time next generation sequencing of cancer genes linked to drug response: Results from a clinical trial. Int. J. Cancer 132, 1547-1555 (2013
43. Dancey, J. E., Bedard, P. L., Onetto, N. & Hudson, T. J. The genetic basis for cancer treatment decisions. Cell 148, 409-420 (2012
44. Institute of Cancerology Gustave Roussy. Official launch of the clinical, academic and international trial WINTHER : A bioinformatics scoring system that predicts the response to known treatments for each patient [online], http://www.igr.fr/en/page/official launch of-winther-5368 (2012
45. Tsimberidou, A. M. et al. Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center Initiative. Clin. Cancer Res. 18, 6373-6383 (2012
46. Wright, J. R. et al. Why cancer patients enter randomized clinical trials: Exploring the factors that influence their decision. J. Clin. Oncol. 22, 4312-4318 (2004
47. Peppercorn, J. et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J. Clin. Oncol. 28, 2635-2640 (2010
48. Lee, J. M. et al. Feasibility and safety of sequential research-related tumor core biopsies in clinical trials. Cancer 119, 1357-1364 (2013
49. Olson, E. M., Lin, N. U., Krop, I. E. & Winer, E. P. The ethical use of mandatory research biopsies. Nat. Rev. Clin. Oncol. 8, 620-625 (2011
50. Tam, A. L. et al. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J. Thorac. Oncol. 8, 436-442 (2013
51. Dowlati, A. et al. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin. Cancer Res. 7, 2971-2976 (2001
52. Nazarian, L. N. et al. Safety and efficacy of sonographically guided random core biopsy for diffuse liver disease. J. Ultrasound Med. 19, 537-541 (2000
53. Caliskan, K. C., Cakmakci, E., Celebi, I. & Basak, M. The importance of experience in percutaneous liver biopsies guided with ultrasonography: A lesion-focused approach. Acad. Radiol. 19, 256-259 (2012
54. Grant, A. & Neuberger, J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 45 (Suppl. 4), IV1-IV11 (1999
55. Robertson, E. G. & Baxter, G. Tumour seeding following percutaneous needle biopsy: The real story! Clin. Radiol. 66, 1007-1014 (2011
56. Agulnik, M., Oza, A. M., Pond, G. R. & Siu, L. L. Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J. Clin. Oncol. 24, 4801-4807 (2006
57. Wolf, S. M. et al. Managing incidental findings and research results in genomic research involving biobanks and archived data sets. Genet. Med. 14, 361-384 (2012
58. Bredenoord, A. L., Kroes, H. Y., Cuppen, E., Parker, M. & van Delden, J. J. Disclosure of individual genetic data to research participants: The debate reconsidered. Trends Genet. 27, 41-47 (2011
59. Gymrek, M., McGuire, A. L., Golan, D., Halperin, E. & Erlich, Y. Identifying personal genomes by surname inference. Science 339, 321-324 (2013
60. Aguilar-Mahecha, A. et al. Making personalized medicine a reality: The challenges of a modern translational research biopsy-driven program in an academic setting: The Segal Cancer Center experience. J. Med. Person. 9, 104-111 (2011
61. Ricci, D. S. et al. Global requirements for DNA sample collections: Results of a survey of 204 ethics committees in 40 countries. Clin. Pharmacol. Ther. 89, 554-561 (2011
62. Katona, T. M. et al. Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma. Am. J. Surg. Pathol. 31, 1029-1037 (2007
63. Liegl, B. et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol. 216, 64-74 (2008
64. Taniguchi, K., Okami, J., Kodama, K., Higashiyama, M. & Kato, K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 99, 929-935 (2008
65. Yancovitz, M. et al. Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in primary and metastatic melanoma. PLoS ONE 7, e29336 (2012
66. Maley, C. C. et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38, 468-473 (2006
67. Mehra, R. et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin. Cancer Res. 17, 3924-3932 (2011
68. Aguilar-Mahecha, A. et al. Study of pre-analytical variables in plasma and breast biopsies to be used for proteomic and genomic studies [online], Biorepositories and Biospecimen Research Branch http://biospecimens.cancer.gov/ meeting/brnsymposium/2011/Posters/Aguilar-508.pdf (2011
69. Diaz, Z. et al. Next-generation biobanking of metastases to enable multidimensional molecular profiling in personalized medicine. Mod. Pathol. http://dx.doi.org/10.1038/modpathol.2013.81.
70. Pusztai, L. et al. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin. Cancer Res. 9, 2406-2415 (2003
71. Willems, S. M., van Deurzen, C. H. & van Diest, P. J. Diagnosis of breast lesions: Fine-needle aspiration cytology or core needle biopsy? A review. J. Clin. Pathol. 65, 287-292 (2012
72. von Renteln, D. et al. A novel flexible cryoprobe for EUS-guided pancreatic biopsies. Gastrointest. Endosc. 77, 784-792 (2013
73. Hetzel, J. et al. Cryobiopsy increases the diagnostic yield of endobronchial biopsy: A multicentre trial. Eur. Respir. J. 39, 685-690 (2012
74. Schumann, C. et al. Cryoprobe biopsy increases the diagnostic yield in endobronchial tumor lesions. J. Thorac. Cardiovasc. Surg. 140, 417-421 (2010
75. Masuda, N., Ohnishi, T., Kawamoto, S., Monden, M. & Okubo, K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res. 27, 4436-4443 (1999
76. Srinivasan, M., Sedmak, D. & Jewell, S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am. J. Pathol. 161, 1961-1971 (2002
77. Klockenbusch, C., O'Hara, J. E. & Kast, J. Advancing formaldehyde cross-linking towards quantitative proteomic applications. Anal. Bioanal. Chem. 404, 1057-1067 (2012
78. Reis, P. P. et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol. 11, 46 (2011
79. Malkov, V. A. et al. Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter Assay System. BMC Res. Notes 2, 80 (2009
80. Holley, T. et al. Deep clonal profiling of formalin fixed paraffin embedded clinical samples. PLoS ONE 7, e50586 (2012
81. Tuononen, K. et al. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS. Genes Chromosomes Cancer 52, 503-511 (2013
82. Florell, S. R. et al. Preservation of RNA for functional genomic studies: A multidisciplinary tumor bank protocol. Mod. Pathol. 14, 116-128 (2001
83. Hatzis, C. et al. Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J. Natl Cancer Inst. 103, 1871-1883 (2011
84. Chowdary, D. et al. Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative. J. Mol. Diagn. 8, 31-39 (2006
85. Przybytkowski, E., Aguilar-Mahecha, A., Nabavi, S., Tonellato, P. J. & Basik, M. Ultradense array CGH and discovery of micro-copy number alterations and gene fusions in the cancer genome. Methods Mol. Biol. 973, 15-38 (2013
86. Belloni, B. et al. Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system. J. Clin. Pathol. 66, 124-135 (2013
87. Kap, M. et al. Histological assessment of PAXgene tissue fixation and stabilization reagents. PLoS ONE 6, e27704 (2011
88. Groelz, D. et al. Non-formalin fixative versus formalin-fixed tissue: A comparison of histology and RNA quality. Exp. Mol. Pathol. 94, 188-194 (2013
89. Botling, J. & Micke, P. Biobanking of fresh frozen tissue from clinical surgical specimens: Transport logistics, sample selection, and histologic characterization. Methods Mol. Biol. 675, 299-306 (2011
90. Ellis, M. et al. Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses. Clin. Cancer Res. 8, 1155-1166 (2002
91. Ono, M. et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res. Treat. 132, 793-805 (2012
92. Loi, S. et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98 J. Clin. Oncol. 31, 860-867 (2013
93. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011
94. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012
95. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012
96. Esgueva, R. et al. Next-generation prostate cancer biobanking: Toward a processing protocol amenable for the International Cancer Genome Consortium. Diagn. Mol. Pathol. 21, 61-68 (2012
97. Golubeva, Y., Salcedo, R., Mueller, C., Liotta, L. A. & Espina, V. Laser capture microdissection for protein and NanoString RNA analysis. Methods Mol. Biol. 931, 213-257 (2013
98. Yuan, Y. et al. Quantitative image analysis of cellular heterogeneity in breast tumors complements genomic profiling. Sci. Transl. Med. 4, 157ra143 (2012
99. Ki, D. H. et al. Whole genome analysis for liver metastasis gene signatures in colorectal cancer. Int. J. Cancer 121, 2005-2012 (2007
100. Türeci, O. et al. Computational dissection of tissue contamination for identification of colon cancer-specific expression profiles. FASEB J. 17, 376-385 (2003
101. Kotorashvili, A. et al. Effective DNA/RNA co-extraction for analysis of microRNAs, mRNAs, and genomic DNA from formalin-fixed paraffin-embedded specimens. PLoS ONE 7, e34683 (2012
102. Soares, A. R., Pereira, P. M. & Santos, M. A. Next-generation sequencing of miRNAs with Roche 454 GS FLX technology: Steps for a successful application. Methods Mol. Biol. 822, 189-204 (2012
103. Moore, H. M., Compton, C. C., Alper, J. & Vaught, J. B. International approaches to advancing biospecimen science. Cancer Epidemiol. Biomarkers Prev. 20, 729-732 (2011
104. Pazzagli, M. et al. SPIDIA-RNA: First external quality assessment for the pre-analytical phase of blood samples used for RNA based analyses. Methods 59, 20-31 (2013
105. Moore, H. M. The NCI Biospecimen Research Network. Biotech. Histochem. 87, 18-23 (2012
106. UC Santa Cruz. UCSC Cancer Genomics Browser [online], https://genome-cancer.ucsc.edu/ (2013
107. Nature Publishing Group. About protocol exchange. Protocol Exchange [online], http://www.nature.com/protocolexchange/about (2013
108. Aguilar-Mahecha, A., Kuzyk, M. A., Domanski, D., Borchers, C. H. & Basik, M. The effect of pre-analytical variability on the measurement of MRM MS based mid- to high-abundance plasma protein biomarkers and a panel of cytokines. PLoS ONE 7, e38290 (2012
109. Begley, C. G. & Ellis, L. M. Drug development: Raise standards for preclinical cancer research. Nature 483, 531-533 (2012
110. Simeon-Dubach, D., Burt, A. D. & Hall, P. A. Quality really matters: The need to improve specimen quality in biomedical research. J. Pathol. http://dx.doi.org/10.1002/path.4117 (2012
111. Ransohoff, D. F. & Gourlay, M. L. Sources of bias in specimens for research about molecular markers for cancer. J. Clin. Oncol. 28, 698-704 (2010
112. Taube, S. E. et al. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J. Natl Cancer Inst. 101, 1453-1463 (2009
113. Silberman, S. Libraries of flesh: The sorry state of human tissue storage. WIRED Magazine (24 May 2010
114. Massett, H. A. et al. Assessing the need for a standardized cancer HUman Biobank (caHUB): Findings from a national survey with cancer researchers. J. Natl Cancer Inst. Monogr. 2011, 8-15 (2011
115. Betsou, F. et al. Standard preanalytical coding for biospecimens: Defining the sample PREanalytical code. Cancer Epidemiol. Biomarkers Prev. 19, 1004-1011 (2010
116. Moore, H. M. et al. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 119, 92-101 (2011
117. Strand, C., Enell, J., Hedenfalk, I. & Fernö, M. RNA quality in frozen breast cancer samples and the influence on gene expression analysis- a comparison of three evaluation methods using microcapillary electrophoresis traces. BMC Mol. Biol. 8, 38 (2007
118. Kennedy, R. D. et al. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J. Clin. Oncol. 29, 4620-4626 (2011
119. Georgiou, C. D., Papapostolou, I. & Grintzalis, K. Protocol for the quantitative assessment of DNA concentration and damage (fragmentation and nicks). Nat. Protoc. 4, 125-131 (2009
120. Esserman, L. J. et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res. Treat. 132, 1049-1062 (2012
121. Nadkarni, P. M., Kemp, R. & Parikh, C. R. Leveraging a clinical research information system to assist biospecimen data and workflow management: A hybrid approach. J. Clin. Bioinforma 1, 22 (2011
122. Welinder, C. et al. Establishing a Southern Swedish Malignant Melanoma OMICS and biobank clinical capability. Clin. Transl. Med. 2, 7 (2013
123. National Cancer Informatics Program. NCIP Launch Meeting Summary Report (05/31/2012). National Cancer Informatics Program Launch Meeting [online], http://ncip.nci.nih.gov/ncip-launch-meeting-presentations/NCIP-Launch- MeetingSummary.pdf (2012
124. Goldman, M. et al. The UCSC Cancer Genomics Browser: Update 2013. Nucleic Acids Res. 41, D949-D954 (2013
125. Schroeder, M. P., Gonzalez-Perez, A. & Lopez Bigas, N. Visualizing multidimensional cancer genomics data. Genome Med. 5, 9 (2013
126. Gomez-Roca, C. A. et al. Sequential research-related biopsies in phase I trials: Acceptance, feasibility and safety. Ann. Oncol. 23, 1301-1306 (2012
127. Baker, M. Biorepositories: Building better biobanks. Nature 486, 141-146 (2012
128. Matzke, E. A. M. et al. Certification for biobanks: The program developed by the Canadian Tumor Repository Network (CTRNet). Biopreserv. Biobank. 10, 426-432 (2012
129. Harris, J. R. et al. Toward a roadmap in global biobanking for health. Eur. J. Hum. Genet. 20, 1105-1111 (2012
130. Watson, R. W., Kay, E. W. & Smith, D. Integrating biobanks: Addressing the practical and ethical issues to deliver a valuable tool for cancer research. Nat. Rev. Cancer 10, 646-651 (2010
131. Fenstermacher, D. A., Wenham, R. M., Rollison, D. E. & Dalton, W. S. Implementing personalized medicine in a cancer center. Cancer J. 17, 528-536 (2011
132. Yachida, S. & Iacobuzio-Donahue, C. A. Evolution and dynamics of pancreatic cancer progression. Oncogene http://dx.doi.org/10.1038/onc.2013.29 (2013
133. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994-1007 (2012
134. Giordano, A. & Cristofanilli, M. CTCs in metastatic breast cancer. Recent Results Cancer Res. 195, 193-201 (2012
135. Jacot, W. et al. Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Res. 13, R133 (2011
136. Rodig, S. J. et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin. Cancer Res. 15, 5216-5223 (2009
137. Calvo, E. & Baselga, J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J. Clin. Oncol. 24, 2158-2163 (2006
138. Mudur, G. Indian scientists object to export of human biological material for research. BMJ 325, 990 (2002
139. Barker, A. D. et al. I SPY 2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97-100 (2009)